Mabpharm Limited (HK:2181) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mabpharm Limited has announced structural changes to its leadership team, effective July 10, 2024, including the appointment of Mr. Cen Jialin as a non-executive Director, Dr. Tao Qian as an independent non-executive Director, and the re-designation and promotion of Dr. Qian Weizhu to executive Director and vice president. Additionally, Mr. Li Yunfeng transitions from the CFO to a vice president role. These appointments and re-designations reflect the company’s strategic adjustments in its executive team.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.